Senti Biosciences Secures Up to $40M in Highly Dilutive Convertible Notes, Leading to Change of Control

summarizeSummary

Senti Biosciences secured up to $40.0 million through highly dilutive convertible notes from its largest shareholder, Celadon Partners, at a deep discount, which will lead to a change of control and includes punitive anti-dilution terms.

check_boxKey Events

• Secured Up to $40.0 Million in Convertible Notes

  The company entered into a Securities Purchase Agreement for up to $40.0 million in Senior Secured Convertible Notes, with an initial $10.0 million tranche from its largest stockholder, Celadon Partners.

• Deep Discount Conversion Price

  The notes are convertible into common stock at an initial price of $0.6261 per share, a significant discount to the current market price of $0.9672.

• Change of Control Triggered

  Upon issuance of the initial notes and stockholder approval, Celadon Partners' beneficial ownership would increase to 54.6% of the outstanding common stock, constituting a change of control.

• Punitive Note Terms

  The notes carry a 200% repayment obligation on a short 6-month maturity if not converted, and include a full-ratchet anti-dilution adjustment, highly unfavorable to existing shareholders.

auto_awesomeAnalysis

Senti Biosciences has entered into a Securities Purchase Agreement for up to $40.0 million in Senior Secured Convertible Notes, with an initial $10.0 million tranche from its largest stockholder, Celadon Partners. This financing is critical for the company's operations and to advance its SENTI-202 product candidate, but comes with extremely unfavorable terms for existing shareholders. The notes are convertible at a deep discount of $0.6261 per share compared to the current stock price of $0.9672, implying significant future dilution. Furthermore, if the initial notes are issued and stockholder approval is obtained (which Celadon has agreed to vote for), Celadon's beneficial ownership would increase to 54.6%, resulting in a change of control. The notes also feature punitive terms, including a 200% repayment obligation on maturity if not converted and a full-ratchet anti-dilution provision, which will further protect the investor at the expense of other shareholders in future dilutive events. The short 6-month maturity period for the notes underscores the company's urgent need for capital and the high risk associated with this financing.